Immunoneutralization of procalcitonin or its component peptides: A promising treatment of sepsis

Clinical Science

Volumn 119, Issue 12, 2010, Pages 515-517

  Becker, Kenneth L ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPROCALCITONIN; CALCITONIN GENE RELATED PEPTIDE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; PEPTIDE; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BLOOD LEVEL; CALC 1 GENE; COMA; DISSEMINATED INTRAVASCULAR CLOTTING; FEVER; GENE; HEART FAILURE; HUMAN; HYPOTENSION; HYPOTHERMIA; IMMUNONEUTRALIZATION; IMMUNOTHERAPY; LEUKOCYTOSIS; LEUKOPENIA; NONHUMAN; NOTE; PRIORITY JOURNAL; SEPSIS; TACHYCARDIA; TACHYPNEA;

ANIMALS; BIOLOGICAL MARKERS; CALCITONIN; HUMANS; IMMUNOTHERAPY; PROTEIN PRECURSORS; RATS; SEPSIS;

EID: 78649856098     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20100367     Document Type: Note

References (11)

1. Slide, E., Tamber, P. S. and Vincent, J.-L. (2003) The surviving sepsis campaign: raising awareness to reduce mortality. Crit Care. 7, 1-2
2. Daniels, R. (2009) Incidence, mortality, and economic burden of sepsis, NHS Evidence: Emergency and Urgent Care (http://www.library.nhs.uk/emergency)
3. Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J. L. and Ramsay, G. (2003) 2001 SCCM/ESICM/ACCP/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250-1256
4. Assicot, M., Gendrel, D., Carsin, H., Raymond, J., Guilbaud, J. and Bohuon, C. (1993) High serum procalcitonin concentration in patients with sepsis and infection. Lancet 341, 515-518
5. Becker, K. L., Snider, R. H. and Nylen, E. S. (2010) Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br. J. Pharmacol. 159, 253-264
6. Nylen, E. S., Whang, K. L., Steinwald, P. M., Snider, R. H., White, J. C. and Becker, K. L. (1998) Procalcitonin increases mortality and procalcitonin-recognizing antiserum improves mortality in an experimental model of sepsis. Crit. Care Med. 26, 1001-1006
7. Wagner, K. E., Martinez, J. M., Vath, S. D., Snider, R. H., Nylen, E. S., Becker, K. L., Müller, B. and White, J. C. (2002) Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit. Care Med. 30, 2313-2321
8. Martinez, J. M., Wagner, K. E., Snider, R. H., Nylen, E. S., Muller, B., Sarani, B., Becker, K. L. and White, J. C. (2001) Late immunoneutralization of procalcitonin arrests the progression of lethal porcine sepsis. Surg. Infect. 2, 193-201
9. Tavares, E. and Miñano, F. J. (2010) Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies. Clin. Sci. 119, 519-534
10. Doi, K., Leelahavanichkul, A., Yuen, P. S. T. and Star, R. A. (2009) Animal models in sepsis and sepsis-induced kidney injury. J. Clin. Invest. 119, 2868-2878
11. Steinbach, P. M., Rau, B., Debard, A. L., Javourez, J. F., Bienvenu, J., Ponzio, A., Bonfà, A., Hubl, W., Demant, T., Külpmann, W. R. et al. (2004) Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor system. Clin. Chem. Lab. Med. 42, 440-449